It will gauge baseline perceptions of biosimilars and evaluate the intent of physicians within the EU5 to prescribe the drugs across a broad array of autoimmune indications. 

The Biosimilar Impact Study will survey 650 rheumatologists, dermatologists and gastroenterologists across UK, France, Germany, Italy and Spain.  It will capture 5000+ patient charts across seven autoimmune indications (Crohn’s Disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, non-radiographic axial spondyloarthritis and ankylosing spondylitis). 

Ipsos Healthcare intends to roll out the current study to the US and other markets shortly – as well as to expand it into other therapy areas according to client demand.

Paul O’Meara, head of Ipsos’ Autoimmune Therapy Monitors said: “The potential impact of biosimilars remains an unknown – but through this study, we will be able to gauge awareness of different biosimilars and manufacturers, evaluate the anticipated benefits and concerns, explore doctors’ anticipated use and identify the most likely patient populations.”